Teriparatide Improves Fracture Healing and Early Functional Recovery in Treatment of Osteoporotic Intertrochanteric Fractures

Tsan-Wen Huang, MD, Po-Yao Chuang, MD, Shih-Jie Lin, MD, Chien-Yin Lee, MD, Kuo-Chin Huang, MD, Hsin-Nung Shih, MD, Mel S. Lee, MD, PhD, Robert Wen-Wei Hsu, MD, and Wun-Jer Shen, MD

Abstract: Osteoporotic intertrochanteric fractures result in serious health problems and decrease health-related quality of life (HRQoL). Faster time-to-union is important for early return to daily activities and reduction of complications. Teriparatide has been shown to accelerate fracture healing, but the literature is sparse on this topic. The aim of this study is to assess whether teriparatide accelerates fracture healing.

Between 2008 and 2014, patients with osteoporotic intertrochanteric fractures who underwent surgical interventions were enrolled in this retrospective cohort study. Group 1 included patients who were not on any osteoporosis medication prior to fracture and who postoperatively received only calcium and vitamin D; patients in Group 2 were not on any osteoporosis medication prior to fracture, and received teriparatide and calcium and vitamin D postoperatively. Patients in Group 3 were those who were on alendronate prior to fracture and postfracture received teriparatide as well as calcium and vitamin D. Demographics, time-to-union, HRQoL (short-form health survey [SF]-12 physical component summary [PCS] and SF-12 mental component summary [MCS]), morbidities, mortalities, and radiographic and functional outcomes between groups were compared.

A total of 189 patients were enrolled in this study. There were 83 patients in Group 1, 47 patients in Group 2, and 59 patients in Group 3. A significantly shorter time-to-union was found in the teriparatide-treated groups (mean, 13.6, 12.3, and 10.6 weeks, respectively [P = 0.002]). With regard to SF-12 PCS, the scores were significantly better in teriparatide-treated groups at 3 months (mean, 19, 28, and 29, respectively [P = 0.002]) and 6 months (mean, 28, 37, and 38, respectively [P = 0.008]). Similar inter-group differences were noted when comparing the pain scores, the ability to get around the house, the ability to get out of the house, and the ability to go shopping at 3 and 6 months.

Complications and mortality were also markedly reduced in the teriparatide-treated groups.

Postoperative use of teriparatide for 6 months appears to be an effective adjunct therapy in the treatment of patients with osteoporotic intertrochanteric fractures. However, because of the limited power of the study, a prospective, randomized, large-scale cohort study is still required for determining the efficacy of teriparatide.

INTRODUCTION

Osteoporotic hip fracture is a serious medical problem and a notable burden on the healthcare system. Many patients will experience significant functional loss, poor health-related quality of life (HRQoL), and higher mortality rate. Previous studies have estimated the cost burden of osteoporosis-related fractures in the United States to be 13.7 to 20.3 billion dollars and 72% of this was due to hip fractures. In Taiwan, the elderly (defined as age ≥ 65 years) will account for 14% and 20% of the total population by 2018 and 2025, respectively. Chen et al performed a nationwide cohort study and concluded that the number of osteoporotic hip fractures in Taiwan is expected to increase 2.7-fold by 2035. The goal of treatment is to allow pain relief, early return to daily activities, and prevent complications. Despite advances in surgical technique and implant design, age-related decreases in bone regenerative capacity and poor bone stock remain problematic.

Recently, there has been heightened interest in using osteoanabolic agents for osteoporosis treatment. Controlled trials have shown that recombinant parathyroid hormone (teriparatide) may play a valuable role in the treatment of fractures. The concept of the so-called ‘‘anabolic window’’ refers to the ability of teriparatide to stimulate processes of bone formation before bone resorption. In contrast to antiresorptive drugs, an acceleration of fracture healing and improved bone strength by directly stimulating proliferation and differentiation of osteoprogenitor cells have been demonstrated in teriparatide-treated animals. In some human trials, it appears to lessen the risk of nonunion and enhance

Editor: Ilke Coskun Benlidayi.
Received: October 23, 2015; revised: January 13, 2016; accepted: April 7, 2016.
From the Department of Orthopedic Surgery (T-WH, P-YC, S-JL, C-YL, K-CH, RW-WH) and Sports Medicine Center (RW-WH), Chang Gung Memorial Hospital, Chiayi, Taiwan; Department of Orthopedic Surgery, Kaohsiung Chang Gung Memorial Hospital, Taiwan (MSL); Department of Orthopedic Surgery, Chang Gung Memorial Hospital, Linkou, Taiwan (H-NS); Chang Gung University, Tao Yuan, Taiwan (T-WH, K-CH, H-NS, MSL, RW-WH); and Po-Cheng Orthopedic Institute, Kaohsiung (W-JS), Taiwan.
Correspondence: Kuo-Chin Huang and Mel S. Lee, No. 6, West Section, Chia-Pu Road, Pu-Tz City, Chia-Yi Hsien 613, Taiwan (e-mail: kc2672@cgmh.org.tw [K-CH] and mellee@cgmh.org.tw [MSL]). The authors have no funding and conflicts of interest to disclose.

Abbreviations: AO/OTA = Arbeitsgemeinschaft für Osteosynthesefragen/Orthopedic Trauma Association, AP = anteroposterior, ASA = American Society of Anesthesiologists, BMD = bone mineral density, BMI = body mass index, DHS = dynamic hip screw, DXA = dual-energy X-ray absorptiometry, HRQoL = health-related quality of life, PTH = parathyroid hormone, SF-12 MCS = short-form health survey mental component summary, SF-12 PCS = short-form health survey physical component summary, TAD = tip-apex distance.
fracture healing.\textsuperscript{19–22} Theoretically, the positive impact of teriparatide on fracture healing is important for early return to daily activities and morbidity and mortality reduction in patients with osteoporotic intertrochanteric fractures. However, the literature is sparse on this topic. This retrospective study aimed to assess whether teriparatide improves osteoporotic intertrochanteric fracture healing. Additional correlation analyses were also conducted to determine the role of supplementary teriparatide in functional and HRQoL recovery as well as reduction of complications.

**METHODS**

Since 2008, all patients who underwent surgery for osteoporotic intertrochanteric fractures at the author’s institution were routinely enrolled in our osteoporosis management program. The merits and risks of osteoporosis treatment based on the World Health Organization guidelines\textsuperscript{23} were explained to the patients. Pharmacologic management including calcium and vitamin D supplementation, antiresorptive drugs (alendronate, ibandronic acid, zoledronic acid, denosumab, and raloxifene), and osteanabolic drugs (teriparatide) was offered. The choice of osteoporosis treatments was decided by the patients themselves (no blinding or randomization) due to regulatory and financial constraints. For the patients who chose recombinant parathyroid hormone (teriparatide), 20 \( \mu \)g/d was given subcutaneously for 18 months beginning on the day of surgery. Drug administration information was documented in our computerized database.

We identified all patients who had intertrochanteric fractures (AO/OTA 31-A1) and who underwent surgery using a dynamic hip screw (DHS) between January 2008 and August 2014. To minimize implant-related confounding factors, patients treated with intramedullary devices such as Gamma nails were not included in this study. A portion of the patients were already taking antiresorptives prior to sustaining their intertrochanteric fracture. The most commonly used drug was alendronate. In order to minimize drug-related variables, we limited this subgroup to alendronate users only. Patients who had received raloxifene, denosumab, ibandronic acid, and zoledronic acid were excluded.

Patients who met the following criteria were also excluded: patients with delirium or dementia and cannot decide their choice of osteoporosis treatments and cannot cooperate to assess the functional outcomes; minimum follow-up of <12 months; subjects with multiple fractures, pathologic fractures, previous ipsilateral hip or femur surgeries, or fractures of the contralateral hip; musculoskeletal conditions that altered bone conditions such as arthrogryposis multiplex congenita, polio-myelitis, cerebral palsy, developmental abnormality, and Down syndrome; patients with contraindications to the use of teriparatide; patients who developed complications related to teriparatide such as generalized weakness and hypercalcemia; patients who were taking teriparatide before the surgery or who had minimum treatment course of <12 months; those who were not ambulatory preoperatively; and incomplete medical records, radiographic analyses, and clinical functional assessments.

The patients were then divided into 3 subgroups: Group 1, patients who were not taking any medication for osteoporosis before the fracture and postfracture received only calcium and vitamin D supplementation (600 mg of calcium and 800 international units of vitamin D3 per day). Group 2, patients who were not taking any medication for osteoporosis before the fracture, and postoperatively received teriparatide and calcium and vitamin D supplementation. Group 3, patients who were taking alendronate before the fracture and received subsequent teriparatide therapy and calcium and vitamin D supplementation after surgery. To determine adequate sample size, a priori power analysis using the hypothesis test with a power of 90% and a significance of 0.05 was done. Based on the report of Vergar et al\textsuperscript{2} and Orive et al\textsuperscript{7} and using short form-12 health status instrument physical component summary (SF-12 PCS) as the primary variable. The assumption that the mean changes in SF-12 PCS among patients with hip fracture was 9 with a standard deviation of 8, the sample size calculation indicated that 44 patients would be required in each group.

**Radiographic Assessment**

All patients enrolled in this study had bone mineral density (BMD) measurements made on the contralateral hip (using the Hologic DXA QDR 4500, Hologic Inc., Waltham, MA), and radiographic examinations, including anteroposterior (AP) view of pelvis, AP and lateral views of the affected hip prior to surgery and at 1 day, 2 weeks, 4 weeks and then monthly postoperation until the fracture had healed. Fracture union was defined as recanalization of the trabeculae or visible bridging callus on both radiograph views,\textsuperscript{24} delayed union was defined as no signs of fracture healing for 24 weeks\textsuperscript{24}; and nonunion was defined as the absence of bone union 36 weeks postoperatively.\textsuperscript{24} The tip-apex distance was measured using AP and lateral radiographs of the affected hip.\textsuperscript{23} The initial postoperative and the last follow-up radiographs were compared, a decrease in the neck-shaft angle was measured as varus collapse,\textsuperscript{24} and the telescoping of the lag screw was measured as lag screw sliding.\textsuperscript{26} The magnitude of bone shortening was measured using the method established by Leung et al.\textsuperscript{27} Failure of treatment was recognized if any of the following events occurred: penetration of the lag screw into the hip joint; breakage of the barrel-plate or its screws; or patient underwent a second operation due to any other cause of implant failure.\textsuperscript{24} The radiographic assessments and BMD of the opposite hip were reviewed and analyzed by an independent surgeon. The intraobserver reliability was assessed according to the method described by Konigsberg et al\textsuperscript{28} and was found to be very good in this study.

**Clinical Assessment**

Preoperative surgical risk was categorized according to the classification of the American Society of Anesthesiologists (ASA).\textsuperscript{29} The hip pain was graded on a 4-point scale: (1) no pain; (2) mild pain, not affecting walking or requiring regular analgesic medication; (3) moderate pain, affecting walking and/or requiring regular medication; and (4) severe pain.\textsuperscript{24} Postoperative functional scores were calculated using the mobility score of Parker and Palmer.\textsuperscript{30} Information on general HRQoL was obtained using the 12-item short form health survey (short-form [SF]-12 physical component summary [PCS] and SF-12 mental component summary [MCS]).\textsuperscript{31} Each subscale is scored from 0 to 100, with higher scores representing better functions. Assessment was performed at 3, 6, 9, and 12 months postoperatively. The pain scores and functional scores were reviewed and analyzed by a research associate. This retrospective study was approved by the Ethics Committee and Institutional Review Board of the Chang Gung Memorial Hospital (102-5918B), and all patients provided signed informed consent.
Statistical Analysis

All data were recorded into an Excel spreadsheet (Microsoft Corp, Redmond, WA) and subsequently copied to a statistical analysis software SPSS version 13.0 (SPSS Inc., Chicago, IL). Statistical analysis was performed by an independent statistician blinded to group allocations. One-way ANOVA test was employed for continuous variables. Scheffe post hoc test was performed for subgroups comparison. The level of statistical significance was set at \( P < 0.05 \). Where appropriate, the \( \chi^2 \) test or the Fisher exact test was used for categorical variables and 1-way ANOVA test for continuous variables.

RESULTS

A total of 255 patients (255 hips) met our inclusion criteria. Among them, 29 patients had incomplete data and 37 patients were lost to follow-up. These patients were excluded; 83 patients were in Group 1 (no meds pre-op, calcium and vitamin D supplementation only post-op), 47 patients were in Group 2 (no meds pre-op, teriparatide post-op), and 59 patients were in Group 3 (alendronate pre-op, teriparatide post-op).

A total of 189 patients were available for analysis, consisting of 61 men and 128 women with a mean age of 82 years (range, 65–89 years) at the time of surgery. The mean body height was 157 cm (range, 138–176 cm), the mean body weight was 54 kg (range, 38–89 kg), and the mean body mass index (BMI) was 23 kg/m\(^2\) (range, 19–36 kg/m\(^2\)). In Group 1, 62 patients were ASA class II and 21 were ASA class III; Group 2 including 32 ASA class II and 15 ASA class III; Group 3 including 42 ASA class II and 17 ASA class III. No statistical differences of ASA classification exists among the 3 groups.

Demographically, there were no statistical differences in sex, age at time of operation, BMI, BMD of contralateral hip, delay between admission and surgery, duration of surgery, and duration of hospital stay (Table 1). The mean of duration of analgesic use after surgery in Groups 1, 2, and 3 were 24.3, 15.1, and 16.1 weeks, respectively \((P < 0.001)\). Scheffe post hoc test revealed that differences existed between Groups 1 and 2, between Groups 1 and 3, but not between Groups 2 and 3 \((P < 0.001, P < 0.001, P = 0.78\), respectively; Table 1). The mean union time in Groups 1, 2, and 3 was 13.6, 12.3, and 10.6 weeks, respectively \((P = 0.002)\). Scheffe post hoc test revealed that differences existed between Groups 1 and 2, between Groups 1 and 3, and between Groups 2 and 3 \((P < 0.001, P < 0.001, P = 0.03\), respectively; Table 1).

With regard to radiographic analyses, there were significant differences in overall varus collapse \((5â€™ \pm 2\) vs \(2\)\(^\circ\) \pm 1\(^\circ\) vs \(0\)\(^\circ\) \pm 1\(^\circ\), \(P < 0.001\)). Scheffe post hoc test showed differences between Groups 1 and 2 and between Groups 1 and 3 \((P < 0.001\) and \(P < 0.001\), respectively). However, no significant differences could be detected between Groups 2 and 3 \((P = 0.99)\). The sliding of the lag screw and the shortening of the femoral were also significantly different among 3 groups \((P < 0.001\) and \(P < 0.001\), respectively; Table 1). Scheffe post hoc test showed statistically significant differences in patients who received teriparatide. However, no statistically significance could be

### Table 1. Demographic and Radiographic Data of Patients

| Variables                  | Group 1 (n=83) | Group 2 (n=47) | Group 3 (n=59) | P Value |
|----------------------------|----------------|----------------|----------------|---------|
| Demographic data           |                |                |                |         |
| Sex                        |                |                |                | 0.31    |
| Male                       | 22 (27%)       | 18 (38%)       | 21 (36%)       |         |
| Female                     | 61 (73%)       | 29 (62%)       | 38 (64%)       |         |
| Age at time of operation, y| 81±8           | 82±10          | 81±8           | 0.81    |
| Body weight, kg            | 54±11          | 56±11          | 54±10          | 0.67    |
| Body mass index, kg/m\(^2\)| 22.4±3.9       | 22.9±4.4       | 22.8±3.1       | 0.48    |
| BMD of contralateral hip, T-score | −3.9±1.2  | −4.2±1.3       | −3.9±1.1       | 0.44    |
| ASA classification         |                |                |                | 0.71    |
| ASA I                      |                |                |                |         |
| ASA II                     | 62 (75%)       | 32 (68%)       | 42 (72%)       |         |
| ASA III                    | 21 (25%)       | 15 (32%)       | 17 (28%)       |         |
| Delay between admission and surgery, h | 23±11  | 22±9           | 23±12          | 0.76    |
| Duration of surgery, min   | 91±14          | 89±12          | 91±13          | 0.79    |
| Duration of hospital stay, d| 8±1            | 8±1            | 8±1            | 0.85    |
| Duration of analgesic use after the surgery, wk | 24.3±8.3\(^a\) | 15.1±4.2 | 16.1±6.7 <0.001 |
| Union time, wk             | 13.6±1.5\(^a\) | 12.3±1.3       | 10.6±1.3       | 0.002   |
| Radiographic data          |                |                |                |         |
| Tip apex distance, mm      | 21±2           | 22±2           | 22±2           | 0.77    |
| Varus collapse, degrees    | 5±2\(^a\)      | 2±1            | 2±1            | <0.001  |
| Sliding of lag screw, mm   | 6±2\(^a\)      | 3±1            | 3±1            | <0.001  |
| Femoral shortening, mm     | 8±6\(^a\)      | 2±1            | 2±1            | <0.001  |

Group 1: patients without supplementary pharmacologic treatment. Group 2: patients treated with teriparatide. Group 3: patients treated with sequential teriparatide. Values are shown as mean±standard deviation or given as the n (%). P values for between-group comparisons were determined by the chi-squared test and Fisher exact test for categorical variables and 1-way ANOVA test for continuous variables.

ASA = American Society of Anesthesiologist, BMD = bone mineral density.

\(^a\)Statistically significant among groups, bold digits indicate \( P \) value <0.05.
found between patients without and with antiresorptive drugs prior to teriparatide therapy ($P = 0.98$ and $P = 0.94$, respectively; Table 1).

Sixteen patients in Group 1, 2 patients in Group 2, and 3 patients in Group 3 died during the follow-up period due to reasons unrelated to the operation ($P < 0.001$). Implant cut-out occurred in 12 hips ($P < 0.001$). Eleven of these were patients in Group 1, 9 hips were treated with bipolar hemiarthroplasty and 2 with total hip arthroplasty. One patient in Group 2 had the lag screw cut out of the femoral head in a fall that occurred 7 weeks after surgery, and underwent bipolar hemiarthroplasty. There was no significant difference in the rate of superficial wound infection, deep wound infection, pneumonia, urinary tract infection, delayed union, nonunion, implant failure, or subsequent fractures among the groups. However, when comparing the cut-out of lag screw among the 3 groups, there were differences between individuals in Groups 1 and 2, and between those in Groups 1 and 3. However, no differences were noted between Groups 2 and 3. Similar intergroup differences were seen when comparing the overall morbidity and mortality (Table 2).

Decreases in SF-12 PCS scores were worse in Group 1 at 3 months (mean, 19, 28, and 29, respectively; $P = 0.002$) and 6 months (mean, 28, 37, and 38, respectively; $P = 0.008$) postoperation. However, Scheffe post hoc test showed no differences between Groups 2 and 3. The scores of SF-12 PCS of the 3 groups did not differ at 9 and 12 months ($P = 0.56$ and $P = 0.79$, respectively; Table 3). Similar intergroup differences were noted when comparing the hip pain scores at 3 months (mean, 2.8, 1.9, and 1.8, respectively [$P < 0.001$]) and 6 months (mean, 2.5, 1.6, and 1.6, respectively [$P < 0.001$]) (Figure 1), the ability to get around the house at 3 months (mean, 1.1, 1.8, and 1.8, respectively [$P < 0.001$]) and 6 months (mean, 1.8, 2.7, and 2.7, respectively [$P < 0.001$]) (Figure 2), the ability to go shopping at 3 months (mean, 0.4, 0.7, and 0.9, respectively [$P < 0.001$]) and 6 months (mean, 0.8, 1.5, and 1.6, respectively [$P < 0.001$]) (Figure 3), and the ability to go shopping at 3 months (mean, 0.2, 0.7, and 0.8, respectively [$P < 0.001$]) and 6 months (mean, 0.3, 0.8, and 1.0, respectively [$P < 0.001$]) (Figure 4). The difference in scores among 3 groups did not achieve statistical significance at the postoperation periods of 9 and 12 months. With regard to SF-12 MCS, there were no significant differences among the groups. With regard to the ability to get around the house, patients in Groups 2 and 3 recovered to baseline level at postoperative 6 months ($P = 0.146$ and $P = 0.205$, respectively). Group 1 recovered to baseline level at postoperative 9 months ($P = 0.111$). Regarding the ability to get out of the house and the ability to go shopping, however, none of the groups had recovered to baseline level by postoperative 12 months. Similarly, lowered scores in SF-12 PCS persisted in all 3 groups during the entire study period. With regard to SF-12 MCS, there were no significant differences in either group between each time point (postoperative 3, 6, 9, and 12 months) and preinjury.

TABLE 2. Postoperative Complications of Patients

| Variables                  | Group 1 (n = 83) | Group 2 (n = 47) | Group 3 (n = 59) | P Value |
|----------------------------|-----------------|-----------------|-----------------|---------|
| Postoperative complications |                 |                 |                 |         |
| Superficial wound infection | 6 (7%)          | 3 (6%)          | 4 (7%)          | 0.98    |
| Deep wound infection       |                 |                 |                 |         |
| Pneumonia                  | 13 (16%)        | 4 (9%)          | 3 (5%)          | 0.11    |
| Urinary tract infection    | 17 (20%)        | 4 (9%)          | 5 (8%)          | 0.06    |
| Delayed union              |                 |                 |                 |         |
| Nonunion                   |                 |                 |                 |         |
| Cutting of the lag screw   | 11 (13%)*       | 1 (2%)          | 0               | 0.002   |
| Implant failure            |                 |                 |                 |         |
| Overall morbidity          | 47*             | 12              | 12              | <0.001  |
| Mortality                  | 16 (19%)*       | 2 (4%)          | 3 (5%)          | 0.007   |
| Subsequent fracture        |                 |                 |                 |         |
| Vertebral fracture         | 15 (18%)        | 5 (11%)         | 6 (10%)         | 0.312   |
| Hip fracture               | 6 (7%)          | 2 (4%)          | 1 (2%)          | 0.307   |
| Wrist fracture             | 6 (7%)          | 3 (6%)          | 3 (5%)          | 0.875   |

Group 1: patients without supplementary pharmacologic treatment. Group 2: patients treated with teriparatide. Group 3: patients treated with sequential teriparatide. Values are shown as mean (standard deviation) or given as the n (%). $P$ values for between-group comparisons were determined by the chi-squared test and Fisher exact test.

*Statistically significant among groups, bold digit indicate $P$ value <0.05.

DISCUSSION

In several studies, teriparatide appeared effective in improving BMD and reducing the rate of subsequent osteoporotic fracture. Recently, there has been heightened interest in the effect of osteoanabolic agents (teriparatide) on acceleration of fracture healing. In contrast to antiresorptive drugs, direct stimulation of bone formation may not only increase bone strength but also facilitate fracture healing. In animal studies, teriparatide has shown efficacy in enhancing the mechanical properties of fracture callus, improving bone-implant contact, and accelerating fracture-healing. Faster fracture-healing in association with teriparatide has been demonstrated in case reports and clinical trials. Aspenberg et al reported a prospective, randomized, double-blind study of 102 postmenopausal women and concluded that teriparatide shortened the time of healing of distal radial fracture as compared with placebo. Bashutski et al reported a randomized clinical trial of 40 patients with periodontitis. Compared with placebo, patients receiving 20 $\mu$g/d teriparatide for 6 weeks had greater resolution of alveolar bone defects, and more rapid
osseous wound healing in the oral cavity. Animal studies, as well as clinical data, suggest that the main clinical advantages of using teriparatide are the acceleration of fracture healing and bone formation enhancement. However, to our knowledge, there is little in the literature regarding the role of teriparatide on the management of osteoporotic intertrochanteric fractures.

In this study, we excluded patients receiving any antiresorptive medication other than alendronate prior to surgery to avoid confounding factors from different medications. In order to avoid confounding factors from different implant and fracture patterns, the present study was focused on AO type 31-A1 fractures and limited to patients treated using a DHS. Under these strict inclusion criteria, we analyzed the effects of teriparatide on patients with osteoporotic intertrochanteric fractures and demonstrated an acceleration of time-to-union for patients with fractures who received teriparatide treatment. This study also found that teriparatide significantly improved SF-12 PCS, relieved pain, decreased analgesic use after surgery and increased mobility score at the postoperative periods of 3 and 6 months, and provided a lower morbidity and mortality rate as compared with the control group.

A high rate of cut-out of the lag screw (13%) was noted in Group 1 (no teriparatide). Patients enrolled in this study had low BMD (mean T-score, −3.9, −4.2, and −3.9, respectively [P value = 0.44]). The poor bone stock results in insufficient contact between fracture fragments and decreases pull-out strength of implants, an excessive sliding of the lag screw occurs and leads to femoral shortening, varus collapse of the proximal fragment, and subsequent cut-out of the lag screw.24,32 In order to address this problem, several techniques using cement and autograft have been developed in order to augment bone stock or to enhance the implant-bone interface.9–11,24 Although cement-augmentation has been widely used for osteoporotic intertrochanteric fractures, it has its own set of failure modes and makes subsequent revision surgeries more complex and technically demanding.24 Autogenous bone graft

| TABLE 3. Clinical Outcome Measures of Patients |
|-----------------------------------------------|
| SF-12 PCS | SF-12 MCS |
| Group 1 (n = 83) | Group 2 (n = 47) | Group 3 (n = 59) | P Value | Group 1 (n = 83) | Group 2 (n = 47) | Group 3 (n = 59) | P Value |
| Preinjury | 19 ± 8 | 28 ± 10 | 28 ± 10 | 3 mo 51 ± 11 | 53 ± 10 | 53 ± 10 | 54 ± 9 | 54 ± 9 | 56 ± 10 | 56 ± 10 | 6 mo 51 ± 11 | 53 ± 10 | 53 ± 10 | 54 ± 9 | 54 ± 9 | 0.903 |
| 9 mo 51 ± 11 | 53 ± 10 | 53 ± 10 | 9 mo 51 ± 11 | 53 ± 10 | 53 ± 10 | 54 ± 9 | 54 ± 9 | 56 ± 10 | 56 ± 10 | 12 mo 51 ± 11 | 53 ± 10 | 53 ± 10 | 54 ± 9 | 54 ± 9 | 0.903 |

Group 1: patients without supplementary pharmacologic treatment. Group 2: patients treated with teriparatide. Group 3: patients treated with sequential teriparatide. Values are shown as mean ± standard deviation (P value). P values for between-group comparison were determined by 1-way ANOVA tests.

MCS = mental component summary, PCS = physical component summary, SF-12 = short-form-12.

Statistically significant (P value < 0.05).

FIGURE 1. Mean hip pain scores. Differences of mean hip pain scores were found among the 3 groups at the postoperation periods of 3 and 6 mo. Mean pain scores at the postoperation periods of 3 mo in Groups 1, 2, and 3 were 2.8, 1.9, and 1.8, respectively. The Scheffe post hoc test revealed that there were differences between Groups 1 and 2 and between Groups 1 and 3 (P < 0.001 and P < 0.001, respectively). No such differences could be detected between Groups 2 and 3 (P = 0.80). Similar intergroup differences were noted at postoperation 6 mo.
is desirable because of its biological characteristics, but there are concerns regarding the poor mechanical properties and donor-site morbidity. Conversely, significant reduction of sliding of lag screw, femoral shortening, varus collapse, and incidence of cut-out of the lag screw was noted in patients who received teriparatide (Table 1). Tao et al study 27 female Sprague–Dawley rats and concluded that 8 weeks of teriparatide use provides a positive effect on repair of femoral metaphyseal defect. This positive effect provides sufficient contact between fracture fragments to decreases excessive sliding of the lag screw and prevents subsequent complications. Concerns exist regarding teriparatide-induced osteosarcoma. Long-term usage and high dose teriparatide contributes to a high incidence of osteosarcoma in Fischer 344 (F344) rats, but no such effect was detected in other animal models and in human trials. Despite higher cost and relatively poor compliance compared with other antiosteoporotic drugs, teriparatide may be a valuable supplemental treatment to enhance fracture healing for osteoporotic intertrochanteric fracture, where poor bone stock and poor bone regenerative capacity challenge orthopedic surgeons. However, it should be mentioned that there are many other factors that influence patients’ outcome (e.g., quality of surgery, orthogeriatric co-management).

The influence of sequential osteoanabolic therapy following antiresorptive drugs is an important area of research. Several studies have shown that beneficial effects on BMD and
improvement of bone strength occur in patients who had been treated with alendronate prior to teriparatide. In addition, the duration of previous alendronate treatment and the time interval between alendronate and teriparatide did not affect the BMD at any skeletal sites. Miller et al found that pronounced responses to increased serum level of the bone formation marker (procollagen type 1 amino-terminal propeptide) in alendronate-treated patients were seen as soon as 1 month after the treatment. The early anabolic effects in sequential teriparatide treatment may contribute to shorter time of fracture healing. Our results were compatible with that concluded by Miller et al. In this study, patients who had been treated with alendronate prior to teriparatide had the shortest time of fracture healing. However, with regard to HRQoL (Table 3), pain relief (Figure 1), and mobility scores (Figures 2—4), no superior responses at postoperative 3 and 6 months in Group 3 were found as compared with Group 2. The most plausible reason for this circumstance is that the union time in both teriparatide-treated groups was <12 weeks. When fractures were healed, patients were able to perform daily activities and had a better HRQoL compared with patients who did not have fracture-healing.

Several limitations in this study must be acknowledged. First, this is a retrospective study with all the inherent weakness and biases of such study designs. Second, the number of patients was small. We excluded patients receiving raloxifene, denosumab, ibandronic acid, and zoledronic acid (any medication other than alendronate) prior to teriparatide to avoid confounding factors from different medication. The strict inclusion criteria for this investigation were designed to limit the variables in the study, but it also reduced the numbers of subjects and limited the power of the study to detect a clinically significant difference. Regarding the role of teriparatide in recovery of HRQoL, although we had more than adequate sample size (44 hips were theoretically required per group) to detect a difference of SF-12 PCS, this study may still be underpowered to demonstrate significant differences. Third, we did not make BMD measurements on the patients at 12 months. This may have been important but it was not in our treatment protocol. Fourth, we did not measure the vitamin D levels at baseline and at the end of therapy. Again, it was not routine in our treatment protocol. Finally, there are 2 different recombinant parathyroid hormones (PTH1-34 and PTH1-84). At present, only teripаратide (recombinant PTH1-34) is available in Taiwan. Although recombinant PTH1-84 also demonstrated clinical effects on fracture healing in postmenopausal women, the authors are not aware of any comparative studies regarding anabolic effects between the 2 drugs.

CONCLUSION

In this retrospective study, 6 months of teriparatide use after surgery was associated with faster fracture-healing, better HRQoL, and less complications. However, a prospective, randomized, large-scale cohort study is still necessary to determine the efficacy of teriparatide in osteoporotic intertrochanteric fractures.

ACKNOWLEDGMENT

The authors wish to thank Miss Yu-Shuan Lin for recording radiographic and functional data and assistance in statistical analyses.

REFERENCES

1. Brauer CA, Coca-Perraillon M, Cutler DM, et al. Incidence and mortality of hip fractures in the United States. JAMA. 2009;302:1573–1579.
2. Shen SH, Huang KC, Tsai YH, et al. Risk analysis for second hip fracture in patients after hip fracture surgery: a nationwide population-based study. J Am Med Dir Assoc. 2014;15:725–731.
3. Chen JJ, Chiang CY, Li YH, et al. Nationwide cohort study of hip fractures: time trends in the incidence rates and projections up to 2035. Osteoporos Int. 2015;26:681–688.
4. Chiu MH, Hwang HF, Lee HD, et al. Effect of fracture type on health-related quality of life among older women in Taiwan. Arch Phys Med Rehabil. 2012;93:512–519.
5. Vergara I, Vrotsou K, Orive M, et al. Factors related to functional prognosis in elderly patients after accidental hip fractures: a prospective cohort study. *BMC Geriatr.* 2014;14:124–132.

6. Orive M, Aguirre U, García-Gutiérrez S, et al. Changes in health-related quality of life and activities of daily living after hip fracture because of a fall in elderly patients: a prospective cohort study. *Int J Clin Pract.* 2015;69:491–500.

7. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. *J Bone Miner Res.* 2007;22:465–475.

8. Council for Economic Planning and Development. Census data and population projection, 2013. http://www.cepd.gov.tw/ml.aspx?csNo=00004855 (accessed Mar 28, 2014).

9. Gehrig LM, Lane JM, O’Connor MI. Osteoporosis: management and treatment strategies for orthopedic surgeons. *Instr Course Lect.* 2009;58:817–832.

10. Schmidt AH, Braman JP, Duwelius PJ, et al. Geriatric trauma: the role of immediate arthroplasty. *J Bone Joint Surg Am.* 2013;95:2230–2239.

11. Lindner T, Kanakaris NK, Marx B, et al. Fractures of the hip and osteoporosis: the role of bone substitutes. *J Bone Joint Surg Br.* 2009;91:294–303.

12. Eriksen EF, Keaveny TM, Gallagher ER, et al. Literature review: the effects of teriparatide therapy at the hip in patients with osteoporosis. *Bone.* 2014;67:246–256.

13. Zhang D, Potty A, Vyas P, et al. The role of recombinant PTH in human fracture healing: a systematic review. *J Orthop Trauma.* 2014;28:57–62.

14. Kleerekoper M, Greenspan SL, Lewiecki EM, et al. Assessing the effects of teriparatide treatment on bone mineral density, bone microarchitecture, and bone strength. *J Bone Joint Surg Am.* 2014;96:e90.

15. Konrnakova M, Stuermer EK, Werner C, et al. Effect of human parathyroid hormone hPTH (1–34) applied at different regimes on fracture healing and muscle in ovarectomized and healthy rats. *Bone.* 2010;47:480–492.

16. Lina IA, Puvanesarajah V, Liaw JA, et al. Quantitative study of parathyroid hormone (1–34) and bone morphogenetic protein-2 on spinal fusion outcomes in a rabbit model of lumbar dorsolateral intertransverse process arthrodesis. *Spine.* 2014;39:347–355.

17. Morimoto T, Kaito T, Kashii M, et al. Effect of intermittent administration of teriparatide (parathyroid hormone 1–34) on bone morphogenetic protein-induced bone formation in a rat model of spinal fusion. *J Bone Joint Surg Am.* 2014;96:e107.

18. Mancilla EE, Brodsky JL, Mehta S, et al. Teriparatide as a systemic treatment for lower extremity nonunion fractures: a case series. *Endocr Pract.* 2015;21:136–142.

19. Wu CC, Wei JC, Hsieh CP, et al. Enhanced healing of sacral and pubic insufficiency fractures by teriparatide. *J Rheumatol.* 2012;39:1306–1307.

20. Borges JL, Freitas A, Bilezikian JP. Accelerated fracture healing with teriparatide. *Arq Bras Endocrinol Metabol.* 2013;57:153–156.

21. Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. *J Bone Miner Res.* 2010;25:404–414.

22. Bashutski JD, Eber RM, Kinney JS, et al. Teriparatide and osteous regeneration in the oral cavity. *N Engl J Med.* 2010;363:2396–2405.

23. Kanis JA, Black D, Cooper C, et al. A new approach to the development of assessment guidelines for osteoporosis. *Osteoporos Int.* 2002;13:527–536.

24. Lee PC, Hsieh PH, Chou YC, et al. Dynamic hip screws for unstable intertrochanteric fractures in elderly patients—encouraging results with a cement augmentation technique. *J Trauma.* 2010;68:954–964.

25. Lindskog DM, Keggi JM. The value of the tip-apex distance in predicting failure of fixation of peritrochanteric fractures of the hip. *J Bone Joint Surg Am.* 1995;77:1058–1064.

26. Tsuchida S, Okumura G, Matsueda M. Postoperative stability on lateral radiographs in the surgical treatment of peritrochanteric hip fractures. *Arch Orthop Trauma Surg.* 2012;132:839–846.

27. Leung F, Gudushauri P, Yuen G, et al. Dynamic hip screw blade fixation for intertrochanteric hip fractures. *J Orthop Surg (Hong Kong).* 2012;20:302–306.

28. Konigsberg B, Hess R, Hartman C, et al. Inter- and intraobserver reliability of two-dimensional CT scan for total knee arthroplasty component malrotation. *Clin Orthop Relat Res.* 2014;472:212–217.

29. American Society of Anesthesiologists. New classification of physical status. *Anesthesiology.* 1963;24:111–114.

30. Parker MJ, Palmer CR. A new mobility score for predicting mortality after hip fracture. *J Bone Joint Surg Br.* 1993;75:797–798.

31. Ware JE, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. *Med Care.* 1996;34:220–233.

32. Wu CC, Tai CL. Effect of lag-screw positions on modes of fixation failure in elderly patients with unstable intertrochanteric fractures of the femur. *J Orthop Surg (Hong Kong).* 2010;18:158–165.

33. Tao ZS, Lv YX, Cui W, et al. Effect of teriparatide on repair of femoral metaphyseal defect in ovarectomized rats. *Z Gerontol Geriatr.* 2015do:10.1007/s00391-015-0949-1.

34. Subbiah V, Madsen VS, Raymond AK, et al. Of mice and men: divergent risks of teriparatide-induced osteosarcoma. *Osteoporos Int.* 2010;21:1041–1045.

35. Thorsteinsson AL, Vestergaard P, Eiken P. Compliance and persistence with treatment with parathyroid hormone for osteoporosis. A Danish national register-based cohort study. *Arch Osteoporos.* 2015;10:535do:10.1007/s11657-015-0237-0.

36. Ettinger B, San Martin J, Crans G, et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. *J Bone Miner Res.* 2004;19:745–751.

37. Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. *J Clin Endocrinol Metab.* 2008;93:852–860.

38. Chevalier Y, Quek E, Borah B, et al. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate. *J Bone Miner Res.* 2004;19:745–751.

39. Misof BM, Paschalis EP, Blount S, et al. Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate. *J Bone Miner Res.* 2010;25:2297–2303.

40. Gamsjaeger S, Buchinger B, Zoehrer R, et al. One year of daily teriparatide treatment for lower extremity nonunion fractures: a case series. *Instr Course Lect.* 2014;67:246–256.

41. Cosman F, Wermers RA, Recknor C, et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or risedronate. *Bone.* 2010;46:41–48.

42. Misof BM, Paschalis EP, Blount S, et al. Effects of teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate. *J Bone Miner Res.* 2010;25:2297–2303.

43. Aminoff MJ, Palmer CR. A new mobility score for predicting mortality after hip fracture. *J Bone Joint Surg Br.* 1993;75:797–798.
42. Keel C, Kraenzlin ME, Kraenzlin CA, et al. Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice. *J Bone Miner Metab.* 2010;28:68–76.

43. Cusano NE, Bilezikian JP. Combination anabolic and antiresorptive therapy for osteoporosis. *Endocrinol Metab Clin North Am.* 2012;41:643–654.

44. Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. *J Clin Endocrinol Metab.* 2008;93:3785–3793.

45. Peichl P, Holzer LA, Maier R, et al. Parathyroid hormone 1–84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. *J Bone Joint Surg Am.* 2011;93:1583–1587.